XMRV accelerates cellular proliferation, transformational activity, and invasiveness of prostate cancer cells by downregulating p27 Kip1

Prostate

Volumn 72, Issue 8, 2012, Pages 886-897

  Pandhare Dash, Jui ^a   Mantri, Chinmay K ^a   Gong, Yuanying ^a   Chen, Zhenbang ^a   Dash, Chandravanu ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

CDK; miR221 222; MMP; p27Kip1; XMRV

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; METALLOPROTEINASE; MICRORNA; MICRORNA 221; MICRORNA 222;

ARTICLE; CANCER GROWTH; CANCER INVASION; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL TRANSFORMATION; DOWN REGULATION; ENZYME ACTIVATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOGENESIS; PROTEIN EXPRESSION; RETROVIRUS; RETROVIRUS INFECTION; XENOTROPIC MURINE LEUKEMIA RELATED RETROVIRUS; ZYMOGRAPHY;

ADENOCARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE PROGRESSION; DOWN-REGULATION; HUMANS; MALE; METALLOPROTEASES; MICRORNAS; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; RNA, MESSENGER; UP-REGULATION; XENOTROPIC MURINE LEUKEMIA VIRUS-RELATED VIRUS;

EID: 84860326188     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21491     Document Type: Article

References (49)

1. Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, Klein EA, Malathi K, Magi-Galluzzi C, Tubbs RR, Ganem D, Silverman RH, DeRisi JL,. Identification of a novel gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog 2006; 2: e25 0211-e25 0225.
2. Schlaberg R, Choe DJ, Brown KR, Thaker HM, Singh IR,. XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc Natl Acad Sci USA 2009; 106: 16351-16356.
3. Arnold RS, Makarova NV, Osunkoya AO, Suppiah S, Scott TA, Johnson NA, Bhosle SM, Liotta D, Hunter E, Marshall FF, Ly H, Molinaro RJ, Blackwell JL, Petros JA,. XMRV infection in patients with prostate cancer: Novel serologic assay and correlation with PCR and FISH. J Urol 2010; 75: 755-761.
4. Knouf EC, Metzger MJ, Mitchell PS, Arroyo JD, Chevillet JR, Tewari M, Miller AD,. Multiple integrated copies and high-level production of the human retrovirus XMRV from 22Rv1 prostate carcinoma cells. J Virol 2009; 83: 7353-7356.
5. Fischer N, Hellwinkel O, Schulz C, Chun FK, Huland H, Aepfelbacher M, Schlomm T,. Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J Clin Virol 2008; 43: 277-283.
6. Hohn O, Krause H, Barbarotto P, Niederstadt L, Beimforde N, Denner J, Miller K, Kurth R, Bannert N,. Lack of evidence for xenotropic murine leukemia virus-related virus (XMRV) in German prostate cancer patients. Retrovirology 2009; 6: 92.
7. Verhaegh GW, de Jong AS, Smit FP, Jannink SA, Melchers WJ, Schalken JA,. Prevalence of human xenotropic murine leukemia virus-related gammaretrovirus (XMRV) in Dutch prostate cancer patients. Prostate 2010; 71: 415-420.
8. Aloia AL, Sfanos KS, Isaacs WB, Zheng Q, Maldarelli F, De Marzo AM, Rein A,. XMRV: A new virus in prostate cancer? Cancer Res 2010; 70: 10028-10033.
9. Silverman RH, Nguyen C, Weight CJ, Klein EA,. The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome. Nat Rev Urol 2010; 7: 392-402.
10. Hué S, Gray ER, Gall A, Katzourakis A, Tan CP, Houldcroft CJ, McLaren S, Pillay D, Futreal A, Garson JA, Pybus OG, Kellam P, Towers GJ,. Disease-associated XMRV sequences are consistent with laboratory contamination. Retrovirology 2010; 7: 111.
11. Robinson MJ, Erlwein OW, Kaye S, Weber J, Cingoz O, Patel A, Walker MM, Kim WJ, Uiprasertkul M, Coffin JM, McClure MO,. Mouse DNA contamination in human tissue tested for XMRV. Retrovirology 2010; 7: 108.
12. Paprotka T, Delviks-Frankenberry KA, Cingöz O, Martinez A, Kung H-J, Tepper CG, Hu W-S, Fivash, MJ Jr, Coffin MJ, Pathak VK,. Recombinant origin of the retrovirus XMRV. Science 2011; 333: 97-101.
13. Singh I, Schlaberg R, Shin CH, Thaker H,. CSHL Retroviral Meeting Presentation, XMRV, or a related virus, is present in a large percentage of men and is localized to the androgen secreting Leydig cells of the testis Abstract number 245.
14. Onlamoon N, Das Gupta J, Sharma P, Rogers K, Suppiah S, Rhea J, Molinaro RJ, Gaughan C, Dong B, Klein EA, Qiu X, Devare S, Schochetman G, Hackett J Jr, Silverman RH, Villinger F,. Infection, viral dissemination, and antibody responses of rhesus macaques exposed to the human gammaretrovirus XMRV. J Virol 2011; 85: 4547-4557.
15. Alian A, Sela-Donenfeld D, Panet A, Eldor A,. Avian hemangioma retrovirus induces cell proliferation via the envelope (env) gene. Virology 2000; 276: 161-168.
16. Liu SL, Miller AD,. Oncogenic transformation by the jaagsiekte sheep retrovirus envelope protein. Oncogene 2007; 26: 789-801.
17. Kim S, Kim N, Dong B, Boren D, Lee SA, Das Gupta J, Gaughan C, Klein EA, Lee C, Silverman RH, Chow SA,. Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer. J Virol 2008; 82: 9964-9977.
18. Metzger MJ, Holguin CJ, Mendoza R, Miller AD,. The prostate cancer-associated human retrovirus XMRV lacks direct transforming activity but can induce low rates of transformation in cultured cells. J Virol 2009; 84: 1874-1880.
19. Dong B, Kim S, Hong S, Das Gupta J, Malathi K, Klein EA, Ganem D, DeRisi JL, Chow SA, Silverman RH,. An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc Natl Acad Sci USA 2007; 104: 1655-1660. (Pubitemid 46214646)
20. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP,. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43: 1809-1818. (Pubitemid 13122588)
21. Dozmorov MG, Hurst RE, Culkin DJ, Kropp BP, Frank MB, Osban J, Penning TM, Lin H-K,. Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells. Prostate 2009; 69: 1077-1090.
22. Sherr CJ, Roberts JM,. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995; 9: 1149-1163.
23. Stacy W, Blain SW, Scher HI, Cordon-Cardo C, Koff A,. p27 as a target for cancer therapeutics. Cancer Cell 2003; 3: 111-115. (Pubitemid 37443384)
24. Kip1 function in tumorigenesis. Genes Dev 2007; 21: 1703-1706. (Pubitemid 47076468)
25. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM,. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996; 85: 733-744.
26. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K,. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996; 85: 707-720.
27. Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 1998; 90: 916-920. (Pubitemid 28304160)
28. KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 2000; 27: 222-224.
29. Sternlicht MD, Werb Z,. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516. (Pubitemid 33096184)
30. Curran S, Murray GI,. Matrix metalloproteinases: Molecular aspects of their roles in tumor invasion and metastasis. Eur J Cancer 2000; 36: 1621-1630. (Pubitemid 30616366)
31. Sato E, Furuta RA, Miyazawa T,. An endogenous murine leukemia viral genome contaminant in a commercial RT-PCR Kit is amplified using standard primers for XMRV. Retrovirology 2010; 7 (1): 110.
32. Sauer CG, Kappeler A, Späth M, Kaden JJ, Michel MS, Mayer D, Bleyl U, Grobholz R,. Expression and activity of matrix metalloproteinases-2 and -9 in serum, core needle biopsies and tissue specimens of prostate cancer patients. Virchows Arch 2004; 444: 518-526. (Pubitemid 38858375)
33. Wood M, Fudge K, Mohler JL, Frost AR, Garcia F, Wang M, Stearns ME,. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 1997; 15: 246-258. (Pubitemid 27240355)
34. Howard, TM, Sheng Z, Wang M, Wu Y, Rasheed S,. Molecular and phylogenetic analyses of a new Amphotropic murine leukemia virus (MuLV-1313). Virol J 2006; 3: 101.
35. Kip1 function: miRNAs come into play. Cell Cycle 2007; 6: 2742-2749. (Pubitemid 350277164)
36. Kip1. J Biol Chem 2007; 282: 23716-23724. (Pubitemid 47311902)
37. Macri E, Loda M,. Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev 1999; 17: 334-337.
38. Blain SW, Scher HI, Cordon-Cardo C, Koff A,. p27 as a target for cancer therapeutics. Cancer Cell 2003; 3: 111-115. (Pubitemid 37443384)
39. Dong B, Silverman RH,. Androgen stimulates transcription and replication of XMRV (xenotropic murine leukemia virus-related virus). J Virol 2009; 84, 1648-1651.
40. Hong S, Klein EA, Das Gupta J, Hanke K, Weight CJ, Nguyen C, Gaughan C, Kim KA, Bannert N, Kirchhoff F, Munch J, Silverman RH,. Fibrils of prostatic acid phosphatase fragments boost infections with XMRV (xenotropic murine leukemia virus-related virus), a human retrovirus associated with prostate cancer. J Virol 2009; 83: 6995-7003.
41. Tsihlias J, Kapusta L, Slingerland J,. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med 1999; 50: 401-423. (Pubitemid 29117075)
42. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKernion JB, Loda M, Reiter RE,. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998; 159: 941-945. (Pubitemid 28106561)
43. Kip1 levels during tumor development. Cancer Cell 2006; 9: 75-76. (Pubitemid 43202657)
44. Servant MJ, Coulombe P, Turgeon B, Meloche S,. Differential regulation of p27(Kip1) expression by mitogenic and hypertrophic factors: Involvement of transcriptional and posttranscriptional mechanisms. J Cell Biol 2000; 148: 543-556.
45. Belletti B, Nicoloso MS, Schiappacassi M, Chimienti E, Berton S, Lovat F, Colombatti A, Baldassarre G,. p27(kip1) functional regulation in human cancer: A potential target for therapeutic designs. Curr Med Chem 2005; 12: 1589-1605. (Pubitemid 40895003)
46. Frankel AD, Young JA,. HIV-1: Fifteen proteins and an RNA. Annu Rev Biochem 1998; 67: 1-25. (Pubitemid 28411121)
47. Yamamoto N, Takase-Yoden S,. Friend murine leukemia virus A8 regulates Env protein expression through an intron sequence. Virology 2009; 385: 115-125.
48. Yamamoto N, Takase-Yoden S,. Analysis of cis-regulatory elements in the 5' untranslated region of murine leukemia virus controlling protein expression. Microbiol Immunol 2009; 53: 140-148.
49. Morris JD, Eddleston AL, Crook T,. Viral infection and cancer. Lancet 1995; 346: 754-758.